Science Friday

Looking Beyond Statins For New Ways To Lower Cholesterol

January 21, 2026

Key Takeaways Copied to clipboard!

  • While statins are the first-line therapy for lowering LDL cholesterol, alternative treatments exist for those who cannot tolerate them, including PCSK9 inhibitors and siRNA medications. 
  • Cardiovascular disease is the leading cause of death globally, emphasizing the critical need for effective cholesterol management strategies, including lifestyle changes and medical interventions. 
  • CRISPR gene-editing technology is being clinically tested to permanently turn off cholesterol-raising genes like PCSK9 in the liver, potentially offering a one-time treatment with lifelong benefits, though long-term safety data is still being collected. 

Segments

Cholesterol Testing and Statin Use
Copied to clipboard!
(00:00:07)
  • Key Takeaway: Cholesterol tests measure HDL (good) and LDL (bad) cholesterol to assess heart attack or stroke risk, often leading to statin therapy if numbers are high.
  • Summary: The yearly physical typically includes a lipid panel to check HDL and LDL levels, which helps determine risk for cardiovascular events. If LDL levels are unfavorable, patients may be prescribed statins. For those who have already experienced a heart attack or stroke, statin therapy is considered essential to lower LDL cholesterol to goal levels.
Statin Decision Guidelines
Copied to clipboard!
(00:01:29)
  • Key Takeaway: Statin initiation for primary prevention relies on clear professional guidelines that assess risk factors, sometimes incorporating calcification scans to guide therapy intensity.
  • Summary: Guidelines from major societies guide decisions on who needs statins, moving beyond just cholesterol numbers for primary prevention. Risk assessment often involves looking at factors like existing atherosclerosis or calcification in heart arteries. Traditional 10-year risk scores can miss younger individuals whose lifetime risk is high but 10-year risk is low.
Physician Judgment in Treatment
Copied to clipboard!
(00:04:13)
  • Key Takeaway: Risk prediction algorithms incorporate factors like family history and ethnicity, but physician judgment remains crucial in deciding between medication and lifestyle changes.
  • Summary: Risk algorithms increasingly consider metrics like blood pressure, diabetes status, smoking history, family history, and ancestral background. Because these estimates are population-geared, individualized decisions about acceptable risk levels lead to differences in physician recommendations regarding starting medication versus prioritizing lifestyle interventions.
Mechanism of Statins
Copied to clipboard!
(00:06:08)
  • Key Takeaway: Statins function by blocking a key enzyme in the liver responsible for synthesizing cholesterol, reducing overall cholesterol levels in the body.
  • Summary: Cholesterol is essential for cell integrity and hormone production, sourced from diet and liver synthesis. Statins target the liver’s backup mechanism, blocking an enzyme necessary for the liver to produce cholesterol from scratch. This action reduces the total amount of cholesterol circulating in the body.
Cholesterol Particle Size Risk
Copied to clipboard!
(00:07:23)
  • Key Takeaway: Smaller LDL cholesterol-carrying particles are more problematic because they penetrate arterial walls more easily, promoting plaque growth and increasing cardiovascular risk.
  • Summary: Cholesterol is carried by lipoproteins, which vary in size; smaller particles are considered more atherogenic. These smaller particles can penetrate the walls of blood vessels more readily than larger ones. This penetration promotes the formation of plaques in the arteries, increasing the long-term risk of cardiovascular disease.
Statin Side Effects and Alternatives
Copied to clipboard!
(00:08:47)
  • Key Takeaway: While muscle aches are a reported side effect, true statin-induced muscle damage is rare, often overshadowed by the nocebo effect; alternatives like PCSK9 inhibitors exist for true intolerants.
  • Summary: The number of people experiencing significant muscle damage (myopathy) from statins is small compared to those who report aches, which can often be attributed to the nocebo effect. True medication-related aches typically affect large, proximal muscle groups symmetrically. For those who truly cannot tolerate statins, alternatives like PCSK9 inhibitors (monoclonal antibodies or siRNA injections) are available.
GLP-1 Effects on Lipids
Copied to clipboard!
(00:13:03)
  • Key Takeaway: GLP-1 medications cause modest, positive lipid changes related to weight loss, but these effects do not explain the primary, significant cardiovascular benefits observed.
  • Summary: GLP-1 receptor agonists lead to slight reductions in LDL cholesterol and increases in HDL cholesterol, alongside triglyceride decreases, all linked to weight loss. The magnitude of these lipid changes is minor compared to the substantial heart health benefits seen in trials. Therefore, the primary mechanism for cardiovascular protection is not lipid lowering.
Statins: Inflammation vs. Cholesterol
Copied to clipboard!
(00:14:41)
  • Key Takeaway: Statins indisputably reduce heart disease risk, primarily through lowering cholesterol, though potential secondary benefits from reducing inflammation remain a long-running, unproven discussion.
  • Summary: The primary, proven benefit of statins is reducing cardiovascular risk through lowering bad cholesterol, supported by decades of clinical trials involving hundreds of thousands of patients. While some suggest statins offer additional benefits by reducing inflammation (pleiotropic effects), the mechanism does not change the conclusive outcome: reduced heart disease and improved life expectancy.
Diet’s Influence on Cholesterol
Copied to clipboard!
(00:17:20)
  • Key Takeaway: Dietary changes offer modest LDL cholesterol reduction compared to medication, but heart-healthy diets like the Mediterranean or DASH diet significantly reduce cardiovascular risk.
  • Summary: High-quality, long-term dietary studies are difficult to conduct, but diet does influence cholesterol levels. Major changes to a typical American diet yield modest LDL lowering, far less than medical therapy. For those avoiding medication, the Mediterranean diet shows strong evidence for reducing heart attack, stroke, and death risk, while the DASH diet is key for hypertension management.
Saturated Fat and Diet Myths
Copied to clipboard!
(00:18:54)
  • Key Takeaway: Saturated fat intake is strongly associated with elevated cholesterol levels, contradicting recent dietary advice suggesting it is beneficial.
  • Summary: There is substantial data linking high saturated fat intake to elevated cholesterol and poorer outcomes, contrary to claims that flip previous learnings. Diets extremely high in saturated fat, like the ketogenic diet, can cause LDL levels comparable to genetic abnormalities. Heart-healthy diets, such as the Mediterranean diet, are supported by large randomized control trials.
CRISPR Gene Editing for Cholesterol
Copied to clipboard!
(00:20:39)
  • Key Takeaway: CRISPR technology aims to permanently turn off liver genes like PCSK9, mimicking a natural genetic advantage seen in 2-3% of the population who have drastically reduced heart disease risk.
  • Summary: The liver regulates cholesterol via genes like PCSK9, which pushes cholesterol levels up; other species naturally lack this active gene. About 2-3% of humans naturally have variants that partially turn off PCSK9, resulting in an 80-90% reduced risk of heart disease throughout their lives. Gene editing seeks to replicate this lifelong, beneficial genetic state via a single treatment.
CRISPR Safety and Future Outlook
Copied to clipboard!
(00:25:05)
  • Key Takeaway: Early clinical trials show CRISPR therapies effectively reduce LDL cholesterol by 50-70% with durable effects, but long-term safety data is paramount, especially for younger patients.
  • Summary: Clinical trials launched in summer 2022 confirm that gene editing works, achieving significant and durable reductions in bad cholesterol levels. The approach is inspired by naturally protected individuals who show no negative consequences from having the gene turned off. The greatest potential benefit lies in treating younger patients early to maximize cumulative lifetime risk reduction, provided long-term safety is confirmed.